CLINICAL TRIALS PROFILE FOR AZULFIDINE

All Clinical Trials for AZULFIDINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007163 ↗	Monoclonal Antibody Treatment of Crohn's Disease	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	2000-12-01	This study will examine the safety and effectiveness of an experimental drug called J695 for treating patients with Crohn's disease-a long-term recurring inflammation of the small and large intestine. This disease is currently treated with steroids, sulfasalazine (Azulfidine), 5-ASA drugs (Pentasa, Asacol), immune suppressants, antibiotics, and an antibody against TNF-alpha. Despite the number and variety of available therapies for Crohn's disease, many patients do not respond adequately to treatment or they develop severe side effects from the medicines. Therefore, new treatments must be developed. J695 is an antibody that is identical to a human antibody but chemically changed so that it can attach to and eliminate an inflammatory chemical made by the body called interleukin-12 (IL-12). Animal studies have shown that eliminating IL-12 with an antibody can prevent inflammation in the gut and can also heal inflammation that has already developed. Patients 18 years of age and older who have had Crohn's disease for at least 4 months may be eligible for this study. Candidates will be screened with a medical history and physical examination, electrocardiogram, chest X-ray, blood and urine tests, stool analysis and possibly a review of medical records. They will complete a Crohn's Disease Activity Index Questionnaire for 7 days. Participants will be randomly assigned to one of two treatment groups, as follows: Group 1 Patients in this group will receive an injection of either J695 or placebo (a solution that does not contain any active medicine) under the skin on day 1 of the study, on day 29, and then weekly for a total of seven injections. After the last injection, patients will be followed for an additional 18 weeks. They will be monitored periodically throughout the study with physical examinations, disease activity index scores, and blood and urine tests. Group 2 Patients in group 2 will receive an injection of J695 or placebo on day 1 of the study and then weekly for a total of six injections. They will be followed for an additional 18 weeks. Patients will be monitored as described above for group 1. Participants may be asked to undergo additional tests as part of a sub-study in this protocol. These include colonoscopies to examine changes in inflammation in the gut and blood tests to analyze changes in the cells and body chemicals that affect the inflammation.
NCT02374021 ↗	Treatments Against RA and Effect on FDG-PET/CT	Active, not recruiting	Columbia University	Phase 4	2016-07-01	In a randomized controlled clinical trial, investigators will compare the effects on [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from two treatment regimens in rheumatoid arthritis (RA) patients deemed methotrexate inadequate responders (MTX-IRs). Two common RA treatments will be compared: triple therapy (sulfasalazine, methotrexate, and hydroxychloroquine) versus tumor necrosis factor (TNF) inhibitor (etanercept or adalimumab, plus background methotrexate for all subjects and hydroxychloroquine for subjects who were taking this at screening).
NCT02374021 ↗	Treatments Against RA and Effect on FDG-PET/CT	Active, not recruiting	Brigham and Women's Hospital	Phase 4	2016-07-01	In a randomized controlled clinical trial, investigators will compare the effects on [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from two treatment regimens in rheumatoid arthritis (RA) patients deemed methotrexate inadequate responders (MTX-IRs). Two common RA treatments will be compared: triple therapy (sulfasalazine, methotrexate, and hydroxychloroquine) versus tumor necrosis factor (TNF) inhibitor (etanercept or adalimumab, plus background methotrexate for all subjects and hydroxychloroquine for subjects who were taking this at screening).
NCT03414502 ↗	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	Recruiting	University of Nebraska	Phase 3	2007-08-01	This is a 16-week, open-label study to identify factors that help predict clinical responses to DMARD therapies for RA (Rheumatoid Arthritis) patients. All patients will receive a starting dose of DMARD medication(s) which may be adjusted by the investigator as needed. If a subject becomes intolerant to a DMARD medication the subject will be withdrawn from the study at the discretion of the investigator. Visits (prior to week 16) where withdrawal is determined to be necessary will be considered end of study. End of study data (week 16) as well as study serum will be collected. (Serum only collected on those subjects who have consented to the addendum Serum and DNA of this study). A portion of the blood collected at baseline, week 8 and week 16 with the addendum portion of the study is for future research and will be utilized attempting to look to detect the generation of superoxide radicals. The radicals have been shown to be associated with inflammation and may correlate with the progression of RA. If this is true, then treatment with RA should decrease the levels of these radicals signaling response to treatment.
NCT04610476 ↗	Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis	Recruiting	University of Erlangen-Nürnberg Medical School	Phase 3	2020-10-19	The rationale for this study is to investigate whether in psoriatic arthritis (PsA) patients in stable remission a reduction or complete discontinuation of immunosuppressive therapy can be achieved in a treat-to-target approach while maintaining in remission. Due to the lack of reliable data that answers the question of how to safely reduce medication in which patients, this study will test a pragmatic treatment algorithm that can be applied in clinical practice and that offers a gradual reduction with escape strategies in order to facilitate the maintenance of remission.

Clinical Trial Conditions for AZULFIDINE

Condition Name

Condition Name for AZULFIDINE
Intervention	Trials
Psoriatic Arthritis	1
Reduction	1
Rheumatoid Arthritis	1
Withdrawal	1

Condition MeSH

Condition MeSH for AZULFIDINE
Intervention	Trials
Arthritis	3
Arthritis, Rheumatoid	2
Arthritis, Psoriatic	1
Crohn Disease	1

Clinical Trial Locations for AZULFIDINE

Trials by Country

Trials by Country for AZULFIDINE
Location	Trials
United States	18
Germany	1

Trials by US State

Trials by US State for AZULFIDINE
Location	Trials
Maryland	2
Washington	1
Texas	1
Pennsylvania	1
Oregon	1

Clinical Trial Progress for AZULFIDINE

Clinical Trial Phase

Clinical Trial Phase for AZULFIDINE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for AZULFIDINE
Clinical Trial Phase	Trials
Recruiting	2
Completed	1
Active, not recruiting	1

Clinical Trial Sponsors for AZULFIDINE

Sponsor Name

Sponsor Name for AZULFIDINE
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	1
Columbia University	1
Brigham and Women's Hospital	1

Sponsor Type

Sponsor Type for AZULFIDINE
Sponsor	Trials
Other	4
NIH	1

AZULFIDINE (sulfasalazine): Clinical Trials Update, Market Analysis, and Projections

Last updated: May 4, 2026

What is AZULFIDINE and where does it sit in the drug pipeline?

AZULFIDINE is the brand name for sulfasalazine (oral). It is an established, off-patent medicine whose clinical use is rooted in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) practice patterns rather than late-stage, novel-drug development.

Clinical-trial reality for sulfasalazine

• Sulfasalazine is used broadly across regions, but the development activity in recent years is dominated by:
  • small investigator-led studies,
  • comparative or adjunct studies,
  • regimen optimization (dose timing, formulation, monitoring),
  • real-world observational work.
• There is no clear signal of a large, late-stage phase program that would drive a “new entrant” market expansion the way an NDA/BLA does.

Implication for a clinical-trials update

• A “pipeline” view for AZULFIDINE is best treated as ongoing evidence generation and regimen refinements, not phase-3 registration cycles.

---

What do clinical trials currently focus on for sulfasalazine?

Across current evidence, sulfasalazine studies cluster in two therapeutic areas:

1) Inflammatory Bowel Disease (IBD)

Common clinical themes include:

• induction and maintenance strategies in ulcerative colitis and Crohn’s disease subsets,
• biomarker or endoscopic endpoints for treatment response,
• steroid-sparing or step-down protocols in standard-of-care regimens.

2) Rheumatoid Arthritis (RA) and related inflammatory conditions

Common clinical themes include:

• comparative tolerability and adherence in real-world settings,
• combination use with conventional DMARDs,
• monitoring approaches that align with long-term safety management.

Clinical-development posture

• Evidence flow is steady, but it does not resemble a typical “late-stage commercialization” cycle because sulfasalazine is not a new molecular entity and the market value is anchored in generic availability and established prescribing.

---

What is the market for AZULFIDINE (sulfasalazine) and how does competition shape it?

Market structure

• AZULFIDINE competes in a market dominated by generic sulfasalazine.
• Brand value depends on:
  • payer and formulary positioning,
  • supply reliability,
  • regional brand persistence where generics face fewer practical switches,
  • clinician familiarity and patient stability on a given product.

Key competitive dynamics

Driver	How it affects AZULFIDINE
Generic substitution	Compresses brand net price and growth rate
Safety-driven switching	Substitution can increase or decrease based on tolerability experience
Formulary design (step therapy)	Impacts access for RA and IBD lines of therapy
Patent status	No brand exclusivity; pricing relies on brand-level contracting
Supply continuity	Influences short-term brand share and pharmacy continuity

Business interpretation

• Expect the brand’s volume to track:
  • total sulfasalazine demand (driven by IBD/RA prevalence and guideline use),
  • plus small brand-share shifts caused by contracting and product availability,
  • not a step-change from new trials.

---

Where does demand come from: RA vs IBD?

Demand drivers

• IBD: Sulfasalazine has sustained use in ulcerative colitis, especially where older first-line options are favored.
• RA: Sulfasalazine has persistent use as part of conventional DMARD strategies, though many regions have greater penetration of newer DMARD classes.

Relative momentum

• IBD cohorts often show steadier long-term therapy continuity than RA populations with higher cycling through multiple DMARD lines.
• Net effect: IBD tends to be the more stable demand backbone for sulfasalazine.

---

What is the pricing and profitability outlook for a brand in a generic market?

With no exclusivity leverage, brand profitability typically depends on:

• net price after rebates and formulary fees,
• manufacturing and distribution cost control,
• pharmacy contract terms,
• switching behavior that keeps stable patients on-brand.

Price expectation

• Brand net pricing generally follows generic competition pressure unless:
  • contracted channel arrangements protect share,
  • specific patient tolerability outcomes favor a consistent product.

---

How should market projection be modeled for AZULFIDINE?

A practical projection model for sulfasalazine brands treats the market as:

1. Base therapy demand (prevalence and guideline inclusion)
2. Competitive substitution (share drift to generics)
3. Utilization shifts (steroid-sparing, step-down protocols, DMARD strategy changes)
4. Supply and logistics (short-term availability shocks)

Projection framework (directional)

• Top-line market (molecules): likely stable to low-growth, tied to IBD/RA epidemiology and guideline use.
• AZULFIDINE brand share: low-growth or flat-to-declining, tied to generic penetration and formulary steering.
• Revenue volatility: more driven by contracting and availability than by clinical-trial launches.

---

What clinical evidence does sulfasalazine still bring that supports routine use?

Sulfasalazine’s clinical position comes from long-standing evidence supporting:

• benefit in UC and certain Crohn’s disease contexts,
• DMARD activity in RA and inflammatory arthritides,
• a known safety profile that supports routine monitoring protocols.

For a brand-level view, the key question is not “does it work,” but:

• whether payers and clinicians continue to include sulfasalazine as a viable option on formularies and treatment algorithms.

---

What actions should business teams take based on this clinical and market posture?

Commercial

• Protect contracted positions where AZULFIDINE is preferred by stable-patient continuity or guideline-based default ordering.
• Use pharmacovigilance and tolerability messaging grounded in routine monitoring rather than “new science.”

Medical affairs

• Align evidence generation with regimen optimization endpoints:
  • adherence, monitoring outcomes, and steroid-sparing in real-world cohorts.
• Focus study designs on pragmatic questions that payers care about (persistence, discontinuation, adverse-event-driven stops).

R&D

• Because sulfasalazine is mature, development is more likely to be:
  • formulation optimization,
  • patient stratification studies,
  • comparative effectiveness work.
• Large registration pathways are unlikely to be business-attractive in a generic-dominated market unless there is a differentiation pathway (e.g., specific formulation advantage with clear differentiation).

---

Key Takeaways

• AZULFIDINE (sulfasalazine) is an established, off-exclusivity product with clinical-trial activity dominated by incremental evidence and regimen optimization, not late-stage registration programs.
• Market growth is constrained by generic sulfasalazine competition, making AZULFIDINE brand performance primarily a share and net-price contracting story rather than a pipeline-driven story.
• Demand is steadier in IBD than in RA due to treatment continuity patterns, but overall market expansion is expected to be low-growth.
• Projections should model base therapy demand and competitive substitution, with revenue volatility linked to contracting and supply rather than to new clinical development milestones.

---

FAQs

1) Is AZULFIDINE still relevant clinically?
Yes. Sulfasalazine remains used in IBD and RA as part of standard-of-care regimens, supported by a long clinical track record and ongoing pragmatic studies.

2) Are there late-stage phase trials that could re-rate AZULFIDINE?
Current development patterns for sulfasalazine are generally incremental rather than late-stage, registration-driven programs typical of new molecular entities.

3) How does generic competition affect AZULFIDINE forecasts?
It compresses brand net pricing and shifts growth to small share changes caused by formulary positioning, contracting, and patient switching behavior.

4) Which therapeutic area is more stable for demand: RA or IBD?
IBD tends to provide more stable utilization because many patients maintain therapy for longer periods, while RA treatment often cycles through multiple DMARDs.

5) What levers most influence AZULFIDINE revenue despite mature science?
Formulary placement, rebate contracting, product continuity (supply), and persistence on-brand versus switching to generics.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. Sulfasalazine search results and study listings. (accessed 2026-05-04).
[2] FDA. Drug label and prescribing information for sulfasalazine products (including AZULFIDINE where applicable). (accessed 2026-05-04).
[3] Global guideline bodies and consensus statements on inflammatory bowel disease and rheumatoid arthritis treatment pathways referencing sulfasalazine use (accessed 2026-05-04).